The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Abstract
Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly( d , l -lactic- co -glycolic acid)- block -poly(ethylene glycol) (PLGA- b -PEG) copolymer and surface functionalized with the A10 2′-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells. These Dtxl-encapsulated nanoparticle-aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) ( P < 0.0004). The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo [body weight loss of 7.7 ± 4% vs. 18 ± 5% for Dtxl-NP-Apt vs. Dtxl-NP at nadir, respectively (mean ± SD); n = 7]. After a single intratumoral injection of Dtxl-NP-Apt bioconjugates, complete tumor reduction was observed in five of seven LNCaP xenograft nude mice (initial tumor volume of ≈300 mm 3 ), and 100% of these animals survived our 109-day study. In contrast, two of seven mice in the Dtxl-NP group had complete tumor reduction with 109-day survivability of only 57%. Dtxl alone had a survivability of only 14%. Saline and nanoparticles without drug were similarly nonefficacious. This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Self-citation(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Self-citationTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.
Kong, G., Braun, R. D., & Dewhirst, M. W. (2000) · PubMed · Cited by 633
Langer, R. (2001) · Science · doi:10.1126/science.1063273 · Cited by 579
Self-citationLupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 458
10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy
Grimm, P. D., Blasko, J. C., Sylvester, J. E., Meier, R. M., & Cavanagh, W. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01601-7 · Cited by 449
Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., Torchilin, V. P., & Munn, L. L. (2002) · PubMed · Cited by 372
Chorny, M., Fishbein, I., Danenberg, H. D., & Golomb, G. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00211-0 · Cited by 370
The Changing Face of Prostate Cancer
Cooperberg, M. R., Moul, J. W., & Carroll, P. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9751 · Cited by 318
Rajasekaran, S. A., Anilkumar, G., Oshima, E., Bowie, J. U., Liu, H., Heston, W., Bander, N. H., & Rajasekaran, A. K. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0731 · Cited by 226
In Vitro Targeting of Synthesized Antibody-Conjugated Dendrimer Nanoparticles
Thomas, T. P., Patri, A. K., Myc, A., Myaing, M. T., Ye, J. Y., Norris, T. B., & Baker, J. R. (2004) · Biomacromolecules · doi:10.1021/bm049704h · Cited by 193
Microfluidic System for Studying the Interaction of Nanoparticles and Microparticles with Cells
Farokhzad, O. C., Khademhosseini, A., Jon, S., Hermmann, A., Cheng, J., Chin, C., Kiselyuk, A., Teply, B., Eng, G., & Langer, R. (2005) · Analytical Chemistry · doi:10.1021/ac050312q · Cited by 174
Self-citationMurphy, G. P., Elgamal, A. A., Su, S. L., et al. (1998) · PubMed · Cited by 168
Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers
Guérin, C. J., Olivi, A., WEINGART, J. D., Lawson, H. C., & Brem, H. (2003) · Investigational New Drugs · doi:10.1023/b:drug.0000006172.65135.3e · Cited by 153
Monoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Murphy, G. P., Elgamal, A. A., Su, S. L., Bostwick, D. G., & Holmes, E. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2259::aid-cncr5>3.0.co;2-t · Cited by 150
Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer
Peschel, R. E., & Colberg, J. W. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01035-0 · Cited by 137
Isolation of a fluorophore-specific DNA aptamer with weak redox activity
Wilson, C., & Szostak, J. W. (1998) · Chemistry & Biology · doi:10.1016/s1074-5521(98)90289-7 · Cited by 107
Design strategies to improve soluble macromolecular delivery constructs
Christie, R. J., & Grainger, D. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00229-6 · Cited by 103
Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin
Pechar, M., Ulbrich, K., Šubr, V., Seymour, L. W., & Schacht, E. H. (2000) · Bioconjugate Chemistry · doi:10.1021/bc990092l · Cited by 97
Vanhoefer, U. J., Cao, S., Harstrick, A., Seeber, S., & Rustum, Y. M. (1997) · Annals of Oncology · doi:10.1023/a:1008290406221 · Cited by 73
Poly(ethyleneglycol)-Coated Nanospheres: Potential Carriers for Intravenous Drug Administration
Gref, R., Minamitake, Y., Peracchia, M. T., Domb, A. J., Trubetskoy, V. S., Torchilin, V. P., & Langer, R. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46803-4_6 · Cited by 66
Self-citationTargeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
Slovin, S. F. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.561 · Cited by 44
Management of Erectile Dysfunction Secondary to Treatment for Localized Prostate Cancer
Telöken, C. (2001) · Cancer Control · doi:10.1177/107327480100800609 · Cited by 18
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Self-citationCancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Self-citationImpact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Self-citationKamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Self-citation
Metadata
- Authors
- Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-04-18
- Volume
- 103
- Issue
- 16
- Pages
- 6315-6320
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2046851174
- Cited by
- 1,663
- References
- 36
- FWCI
- 45.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.